KRAKOW, Poland, May 16, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
See the article here:
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Related Post
- Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - May 14th, 2024
- Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - May 14th, 2024
- Cardiff Oncology to Present at Upcoming Investor Conferences in May - May 14th, 2024
- scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference - May 14th, 2024
- Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results - May 14th, 2024
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 - May 14th, 2024
- PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock... - May 14th, 2024
- Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones - May 14th, 2024
- Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights - May 14th, 2024
- Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights - May 14th, 2024
- Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights - May 14th, 2024
- Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update - May 14th, 2024
- Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - May 14th, 2024
- Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update - May 14th, 2024
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock - May 14th, 2024
- HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory... - May 14th, 2024
- Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights - May 14th, 2024
- Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024 - May 14th, 2024
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update - May 14th, 2024
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in... - May 14th, 2024
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs - April 16th, 2024
- Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research... - April 16th, 2024
- Redemption Date Announced for Warrants - April 16th, 2024
- Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products - April 16th, 2024
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors - April 16th, 2024
- Publication Annual Report – Annual Shareholders' Meeting - April 16th, 2024
- Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American... - April 16th, 2024
- Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort - April 16th, 2024
- New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for... - April 16th, 2024
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million - April 16th, 2024
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC - April 16th, 2024
- Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders - April 16th, 2024
- GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents - April 16th, 2024
- TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation - April 16th, 2024
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - April 16th, 2024
- BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement - April 16th, 2024
- Faron Confirms Plans for the Coming Months Under New Leadership - April 16th, 2024
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 - April 16th, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease - April 16th, 2024
- Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 - April 16th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
- Genmab Announces Initiation of Share Buy-Back Program - March 18th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
- Financière de Tubize - Annual report 2023 - March 18th, 2024
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
- Pharvaris Announces Extraordinary Meeting of Shareholders - February 18th, 2024
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right - February 18th, 2024
- Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 - February 18th, 2024
- Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent... - February 18th, 2024
- Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results - February 18th, 2024
- Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - February 18th, 2024
- Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’... - February 18th, 2024
- Mdxhealth Announces Resignation of Board Member - February 18th, 2024
- Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020... - February 18th, 2024
- ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 - February 18th, 2024
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies - February 18th, 2024
- Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma - February 18th, 2024
- Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 - February 18th, 2024
- Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders - February 18th, 2024
- Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal - February 18th, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - February 18th, 2024
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments - January 25th, 2024
- CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a... - January 25th, 2024
- nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends - January 25th, 2024